BeiGene Starts Second China Pivotal Phase II Trial of PD-1 Drug

BeiGene, a Beijing oncology company, has started the second pivotal China Phase II trial of its PD-1 immuno-oncology drug, BGB-A317, in patients with bladder cancer. The first pivotal trial is testing BGB-A317 in patients with Hodgkin lymphoma. Last week, BeiGene announced positive preliminary data from a Phase I trial of the candidate in patients with advanced liver cancer. In the trial, BGB-A317 was generally well-tolerated and showed signs of efficacy in the heavily pre-treated patients. The news sent BeiGene's stock 21% higher to $54.46, an all-time high. More details.... Stock Symbol: (NSDQ: BGNE) Share this with colleagues: // //